RxDoctor Payments Data

Robin Murdock, APRN

Family · Derby, CTNPI 1861943375

Payments from drug & device makers

$3,657in general payments, 2019–2025

Across 199 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Collegium Pharmaceutical, Inc.$691
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$249
  • Teva Pharmaceuticals USA, Inc.$244
  • Avanir Pharmaceuticals, Inc.$232
  • Amgen$209
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,651100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,657 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$37,923
Medicare patients
55
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl56$52,297
RelistorMethylnaltrexone Bromide13$32,559
Buprenorphine84$18,630
Levorphanol Tartrate13$16,234
Oxycodone Hcl715$14,451
ZtlidoLidocaine21$12,880
MovantikNaloxegol Oxalate29$11,788
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen392$10,530
Xtampza ErOxycodone Myristate27$10,427
LinzessLinaclotide16$8,631
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$5,078
Tizanidine Hcl181$3,521
Pregabalin99$2,720
Tramadol Hcl ErTramadol Hcl30$2,497
Morphine Sulfate ErMorphine Sulfate65$2,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$691$62,72483 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$249$32,55913 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl, Buprenorphine-Naloxone, Morphine Sulfate$19$20,982144 claims
Scilex Pharmaceuticals Inc.Ztlido$95$12,88021 claims
Redhill Biopharma Inc.Movantik$16$11,78829 claims
AbbVieLinzess$737$8,63116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →